Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer.

By M. Gordon, K. Margolin, M. Talpaz, G. Sledge, E. Holmgren, R. Benjamin, Susan Stalter, S. Shak, D. Adelman. Journal of Clinical Oncology, 2001

945 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. (2007, background): “chemotherapy.(8,9) Improvements in clinical efficacy have been described when bevacizumab is added to fluorouracil-based chemotherapy for metastatic colorectal cancer.”
ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. (2002, background): “These include the use of antibodies for ligand sequestration or receptor antagonism, which are currently under clinical investigation (38, 39).”
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer (2004, background): “The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency.”
Ten years of anti-vascular endothelial growth factor therapy (2016, background): “In Phase I clinical trials, bevacizumab monotherapy was generally well tolerated, with no severe (grade III or grade IV) adverse events 68 ; typical side effects of bevacizumab were hypertension and mild proteinuria 69 .”